References
- Bardin C W, Lipsett M B. Testosterone and androstene-dione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967; 46: 891
- Colby H D, Skelton F R, Brownie A C. Testosterone-induced hypertension in the rat. Endocrinology 1970; 86: 1093
- Diamont Y Z, Rimon E, Evron S. High incidence of pre-eclamptic toxemia in patients with polycystic ovarian disease. Europ J Obstet Gynecol Reprod Biol 1982; 14: 199
- Buttram V C, Jr, Vaquero C. Post-ovarian wedge resection adhesive disease. Fertil Steril 1975; 26: 874
- Abraham G E, Buster J E. Peripheral and ovarian steroids in ovarian hyperthecosis. Obstet Gynecol 1976; 47: 581
- Blum H, Kaufman H, Marirus R, Rusecki Y, Chovers I. Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. Obstet Gynecol 1981; 57: 661
- Lewis M J. Bromocriptine in hypertension. Brit J Hosp Med 1978; 20: 661
- Flückiger E., Bayliss R IS, Turner P, Maclay W P. Pharmacological and clinical aspects of bromocriptine. Proceedings of a symposium held at the Royal College of Physicians. MCS Consultants, London 1976; 12–14
- McCall A L, Stern J, Dale S L, Melby J C. Adrenal steroidgenesis in methylandrostenediol-induced hypertension. Endocrinology 1978; 103: 1
- Skelton F R, Brownie A C, Nickerson P A, Molteni A, Gallant S, Colby H D. Adrenal cortical dysfunction as a basis for experimental hypertensive disease. Cir Res, 24& 25(Suppl. 1)35–56
- Besser G M, Thorner M O, Wass J AH. Therapeutic use of bromocriptine and growth hormone release inhibiting hormone. Prog Reprod Biol 1977; 2: 261